Oxford, UK – 1st April 2021 – OxSonics® Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer today announced the appointment of Dr Allison Jeynes as non-executive Chair of the Board of Directors.
Allison Jeynes, MD, FFPM (UK), is a trained clinician with more than 25 years of senior leadership experience in the pharmaceutical industry. Currently, she serves as Chief Executive Officer at Avillion LLP, a London-based drug development company focused on co-development and financing of late-stage pharmaceuticals where she is responsible for identifying high-potential opportunities to fund programs to approval. Previously, she held senior clinical development roles at Wyeth, BMS, and Novartis and has secured numerous US and EU drug approvals. Dr Jeynes also serves as a non-executive director of Agenus Inc. and Anaveon AG and is a special advisor to Abingworth LLP and senior advisor to Blackstone Group Inc.
Allison Jeynes commented: “I’m delighted to be joining as non-executive Chair of Oxsonics and believe that my prior clinical oncology experience as well as pharma and investor network will help Oxsonics deliver on its journey to bring this exciting technology to patients. I look forward to working alongside Colin, CEO and the rest of the experienced Board to help ensure the Company achieves its goals.”
“I’m delighted to welcome Allison as Chair of the Board. Allison has an enviable track record in the successful delivery of clinical programs both from within the pharmaceutical industry and more recently through her leadership at Avillion. I very much look forward to working with Allison to further strengthen and build the pipeline of clinical opportunities that OxSonics’ drug delivery platform, SonoTran®, has to offer patients,” said Colin Story, OxSonics Therapeutics Co-founder and CEO.
– ENDS –
About OxSonics Therapeutics
OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.
The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.